Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis

Published 2017 View Full Article

Authors

Keywords

Malignancies, Tofacitinib, JAK inhibitors, Biological disease-modifying antirheumatic drugs

Journal

SEMINARS IN ARTHRITIS AND RHEUMATISM

Volume 47, Issue 2, Pages 149-156

Publisher

Elsevier BV

Online

2017-02-16

DOI

10.1016/j.semarthrit.2017.02.007

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started